<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01169519</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00025220</org_study_id>
    <nct_id>NCT01169519</nct_id>
  </id_info>
  <brief_title>Sildenafil in Single Ventricle Patients</brief_title>
  <official_title>Safety, Pharmacokinetics and Hemodynamic Efficacy of Sildenafil in Single Ventricle Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with single ventricle anatomy undergo staged surgical palliation. The result is an
      &quot;in series&quot; circulation with pulmonary blood flow and cardiac output directly related to
      pulmonary vascular resistance. While surgical outcomes have improved, the physiology of the
      single ventricle palliation results in continued long term attrition. Elevated pulmonary
      vascular resistance and impaired systemic ventricular function are important risk factors for
      failure of single ventricle palliation.

      Sildenafil is a pulmonary vasodilator and has been shown to improve cardiac contractility in
      the pressure overloaded right ventricle.

      The investigators will assess the safety, pharmacokinetics and hemodynamic efficacy of
      sildenafil in single ventricle patients following stage II and III surgical palliation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Sildenafil Plasma Concentration</measure>
    <time_frame>5 minutes after completion of sildenafil infusion</time_frame>
    <description>Assessment of peak sildenafil plasma concentration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic Safety and Efficacy</measure>
    <time_frame>10 minutes after completion of sildenafil infusion</time_frame>
    <description>Assessment of pulmonary vascular resistance</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Heart Disease</condition>
  <arm_group>
    <arm_group_label>Sildenafil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pharmacokinetic and hemodynamic evaluation following sildenafil administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil by injection</intervention_name>
    <description>Sildenafil 0.125mg/kg injection over 20min</description>
    <arm_group_label>Sildenafil</arm_group_label>
    <other_name>Revatio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil by injection</intervention_name>
    <description>Sildenafil 0.25mg/kg injection over 20min</description>
    <arm_group_label>Sildenafil</arm_group_label>
    <other_name>Revatio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil by injection</intervention_name>
    <description>Sildenafil 0.35mg/kg by injection over 20min</description>
    <arm_group_label>Sildenafil</arm_group_label>
    <other_name>Revatio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil by injection</intervention_name>
    <description>Sildenafil 0.45mg/kg by injection over 20min</description>
    <arm_group_label>Sildenafil</arm_group_label>
    <other_name>Revatio</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 3 months; ≤120 months.

          2. History of congenital heart disease with severe hypoplasia of a right or left
             ventricle.

          3. Undergoing cardiac catheterization as part of standard clinical care.

          4. Availability and willingness of the parent/legally authorized representative to
             provide written informed consent.

        Exclusion Criteria:

          1. History of serious adverse event related to sildenafil administration.

          2. History of sildenafil exposure within 48 hours of the study.

          3. Presence of pulmonary venous obstruction.

          4. Treatment with organic nitrates or alpha blockade therapy.

          5. Contraindication to cardiac catheterization as determined by the attending
             cardiologist and including:

               1. Significant hemodynamic instability.

               2. Sepsis.

               3. Need for Extra-Corporeal Membrane Oxygenation (ECMO) support.

               4. Venous occlusion precluding adequate access.

               5. Recent systemic illness.

          6. Renal failure defined as serum creatinine &gt; 2 times higher than the upper limit of
             normal.

          7. Liver dysfunction defined as alanine aminotransferase or aspartate aminotransferase &gt;
             3 times higher than the upper limit of normal.

          8. Thrombocytopenia defined as a platelet count &lt; 50 000 cells/µL.

          9. Leukopenia defined as white blood cells &lt; 2500 cells/µL.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>120 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin D Hill, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hill KD, Tunks RD, Barker PC, Benjamin DK Jr, Cohen-Wolkowiez M, Fleming GA, Laughon M, Li JS. Sildenafil exposure and hemodynamic effect after stage II single-ventricle surgery. Pediatr Crit Care Med. 2013 Jul;14(6):593-600. doi: 10.1097/PCC.0b013e31828aa5ee.</citation>
    <PMID>23823195</PMID>
  </results_reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2010</study_first_submitted>
  <study_first_submitted_qc>July 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2010</study_first_posted>
  <results_first_submitted>July 29, 2013</results_first_submitted>
  <results_first_submitted_qc>October 10, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 5, 2013</results_first_posted>
  <last_update_submitted>October 10, 2013</last_update_submitted>
  <last_update_submitted_qc>October 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypoplastic left heart syndrome</keyword>
  <keyword>Hypoplastic right heart syndrome</keyword>
  <keyword>Superior cavopulmonary anastomosis</keyword>
  <keyword>Total cavopulmonary anastomosis</keyword>
  <keyword>Children with single ventricle anatomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients recruited upon presentation for elective Pre-stage II or stage III catheterization. The first patient was recruited on 4/14/2011 and the final patient was enrolled on 11/29/2012</recruitment_details>
      <pre_assignment_details>Enrolled subjects were excluded from trial participation if they demonstrated baseline hemodynamics suggesting that they would not tolerate sildenafil infusion (e.g. baseline hypotension)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Baseline/Sildenafil</title>
          <description>Assessment of baseline hemodynamics followed by sildenafil infusion with repeat assessment of hemodynamics</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21">This was a pre-post study, All patients receiving a baseline assessment, also received sildenafil.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Overall 21 subjects were enrolled and all subjects received a baseline assessment followed by sildenafil administration.</population>
      <group_list>
        <group group_id="B1">
          <title>Sildenafil</title>
          <description>Pharmacokinetic and hemodynamic evaluation following sildenafil administration
Sildenafil by injection : Sildenafil 0.45mg/kg by injection over 20min
Sildenafil by injection : Sildenafil 0.25mg/kg injection over 20min
Sildenafil by injection : Sildenafil 0.35mg/kg by injection over 20min
Sildenafil by injection : Sildenafil 0.125mg/kg injection over 20min</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.4" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Sildenafil Plasma Concentration</title>
        <description>Assessment of peak sildenafil plasma concentration.</description>
        <time_frame>5 minutes after completion of sildenafil infusion</time_frame>
        <population>3 patients were enrolled in this group but in 1 participant, an inadequate plasma sample volume prevented accurate determination of sildenafil concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>Peak Sildenafil Level (ng/mL) for Dose = 0.125mg/kg</title>
            <description>Maximum sildenafil plasma concentration measured 5 minutes after completion of sildenafil infusion</description>
          </group>
          <group group_id="O2">
            <title>Peak Sildenafil Level (ng/mL) for Dose = 0.35mg/kg</title>
            <description>Maximum sildenafil plasma concentration measured 5 minutes after completion of sildenafil infusion</description>
          </group>
          <group group_id="O3">
            <title>Peak Sildenafil Level (ng/mL) for Dose = 0.45mg/kg</title>
            <description>Maximum sildenafil plasma concentration measured 5 minutes after completion of sildenafil infusion</description>
          </group>
          <group group_id="O4">
            <title>Peak Sildenafil Level (ng/mL) for Dose = 0.25mg/kg</title>
            <description>Maximum sildenafil plasma concentration measured 5 minutes after completion of sildenafil infusionplasma concentration</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Sildenafil Plasma Concentration</title>
          <description>Assessment of peak sildenafil plasma concentration.</description>
          <population>3 patients were enrolled in this group but in 1 participant, an inadequate plasma sample volume prevented accurate determination of sildenafil concentration.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181" spread="126"/>
                    <measurement group_id="O2" value="515" spread="98"/>
                    <measurement group_id="O3" value="545" spread="185"/>
                    <measurement group_id="O4" value="202" spread="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemodynamic Safety and Efficacy</title>
        <description>Assessment of pulmonary vascular resistance</description>
        <time_frame>10 minutes after completion of sildenafil infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Assessment of baseline hemodynamics</description>
          </group>
          <group group_id="O2">
            <title>Sildenafil</title>
            <description>Pharmacokinetic and hemodynamic evaluation following sildenafil administration
Sildenafil by injection : Sildenafil 0.45mg/kg by injection over 20min
Sildenafil by injection : Sildenafil 0.25mg/kg injection over 20min
Sildenafil by injection : Sildenafil 0.35mg/kg by injection over 20min
Sildenafil by injection : Sildenafil 0.125mg/kg injection over 20min</description>
          </group>
        </group_list>
        <measure>
          <title>Hemodynamic Safety and Efficacy</title>
          <description>Assessment of pulmonary vascular resistance</description>
          <units>Wood units * m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1.7" upper_limit="3.0"/>
                    <measurement group_id="O2" value="1.6" lower_limit="1.2" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dose = 0.125mg/kg</title>
          <description>Subjects receiving a sildenafil dose of 0.125mg/kg IV over 20 min</description>
        </group>
        <group group_id="E2">
          <title>Dose = 0.25mg/kg</title>
          <description>Subjects receiving a sildenafil dose of 0.25mg/kg IV over 20 min</description>
        </group>
        <group group_id="E3">
          <title>Dose = 0.35mg/kg</title>
          <description>Subjects receiving a sildenafil dose of 0.35mg/kg IV over 20 min</description>
        </group>
        <group group_id="E4">
          <title>Dose = 0.45mg/kg</title>
          <description>Subjects receiving a sildenafil dose of 0.45mg/kg IV over 20 min</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kevin Hill</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>919-668-8305</phone>
      <email>kevin.hill@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

